JP2006506463A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006506463A5 JP2006506463A5 JP2005502127A JP2005502127A JP2006506463A5 JP 2006506463 A5 JP2006506463 A5 JP 2006506463A5 JP 2005502127 A JP2005502127 A JP 2005502127A JP 2005502127 A JP2005502127 A JP 2005502127A JP 2006506463 A5 JP2006506463 A5 JP 2006506463A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- pyrrolidin
- ethoxy
- propoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 cyano, isocyano, nitro, hydroxy, mercapto, amino, formyl Chemical group 0.000 claims 259
- 125000000217 alkyl group Chemical group 0.000 claims 76
- 125000001424 substituent group Chemical group 0.000 claims 54
- 125000000623 heterocyclic group Chemical group 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 20
- 150000003246 quinazolines Chemical class 0.000 claims 19
- 125000001309 chloro group Chemical group Cl* 0.000 claims 18
- 229910052757 nitrogen Inorganic materials 0.000 claims 16
- 229910052760 oxygen Inorganic materials 0.000 claims 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 15
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 125000001153 fluoro group Chemical group F* 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 11
- 239000002253 acid Substances 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 125000005236 alkanoylamino group Chemical group 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 7
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 7
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 6
- 125000003282 alkyl amino group Chemical group 0.000 claims 6
- 125000001246 bromo group Chemical group Br* 0.000 claims 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 6
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 claims 5
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims 5
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 5
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims 5
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 5
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 5
- 125000001589 carboacyl group Chemical group 0.000 claims 5
- 238000006243 chemical reaction Methods 0.000 claims 5
- 125000000524 functional group Chemical group 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 5
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 5
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 4
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 claims 4
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 125000006319 alkynyl amino group Chemical group 0.000 claims 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 claims 4
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 4
- 229920002554 vinyl polymer Polymers 0.000 claims 4
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims 3
- 125000004423 acyloxy group Chemical group 0.000 claims 3
- 125000003302 alkenyloxy group Chemical group 0.000 claims 3
- 125000005133 alkynyloxy group Chemical group 0.000 claims 3
- 150000001412 amines Chemical class 0.000 claims 3
- 238000003780 insertion Methods 0.000 claims 3
- 230000037431 insertion Effects 0.000 claims 3
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 3
- 125000006239 protecting group Chemical group 0.000 claims 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 3
- HNEGJTWNOOWEMH-UHFFFAOYSA-N 1-fluoropropane Chemical group [CH2]CCF HNEGJTWNOOWEMH-UHFFFAOYSA-N 0.000 claims 2
- PPQDYOBQQWPTIS-UHFFFAOYSA-N 2-(diethylamino)acetamide Chemical compound CCN(CC)CC(N)=O PPQDYOBQQWPTIS-UHFFFAOYSA-N 0.000 claims 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- CZRKDEZQBFIZHM-UHFFFAOYSA-N CN(C(COC(C)=O)=O)NCCC Chemical compound CN(C(COC(C)=O)=O)NCCC CZRKDEZQBFIZHM-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims 2
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 claims 2
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 2
- 229940080818 propionamide Drugs 0.000 claims 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- XQGNSUGMUSXKKB-UHFFFAOYSA-N 1-[4-[2-[4-[(6-chloro-[1,3]dioxolo[4,5-b]pyridin-7-yl)amino]-5-(oxan-4-yloxy)quinazolin-7-yl]oxyethyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CN=C3OCOC3=2)Cl)=NC=N2)C2=C1 XQGNSUGMUSXKKB-UHFFFAOYSA-N 0.000 claims 1
- CETXQBFLIVLDTF-UHFFFAOYSA-N 1-[4-[2-[4-[(6-chloro-[1,3]dioxolo[4,5-b]pyridin-7-yl)amino]-5-propan-2-yloxyquinazolin-7-yl]oxyethyl]piperazin-1-yl]-2-(dimethylamino)ethanone Chemical compound C=1C2=NC=NC(NC=3C(=CN=C4OCOC4=3)Cl)=C2C(OC(C)C)=CC=1OCCN1CCN(C(=O)CN(C)C)CC1 CETXQBFLIVLDTF-UHFFFAOYSA-N 0.000 claims 1
- MVWATCATLSSVBH-UHFFFAOYSA-N 1-[4-[2-[4-[(6-chloro-[1,3]dioxolo[4,5-b]pyridin-7-yl)amino]-5-propan-2-yloxyquinazolin-7-yl]oxyethyl]piperazin-1-yl]ethanone Chemical compound C=1C2=NC=NC(NC=3C(=CN=C4OCOC4=3)Cl)=C2C(OC(C)C)=CC=1OCCN1CCN(C(C)=O)CC1 MVWATCATLSSVBH-UHFFFAOYSA-N 0.000 claims 1
- XACGJHGLWHFNKU-UHFFFAOYSA-N 2-[4-[2-[4-[(6-chloro-[1,3]dioxolo[4,5-b]pyridin-7-yl)amino]-5-propan-2-yloxyquinazolin-7-yl]oxyethyl]piperazin-1-yl]ethanol Chemical compound C=1C2=NC=NC(NC=3C(=CN=C4OCOC4=3)Cl)=C2C(OC(C)C)=CC=1OCCN1CCN(CCO)CC1 XACGJHGLWHFNKU-UHFFFAOYSA-N 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- SDYDJNLCQKFKIL-UHFFFAOYSA-N 6-chloro-n-[5-(oxan-4-yloxy)-7-[2-(4-prop-2-ynylpiperazin-1-yl)ethoxy]quinazolin-4-yl]-[1,3]dioxolo[4,5-b]pyridin-7-amine Chemical compound ClC1=CN=C2OCOC2=C1NC(C1=C(OC2CCOCC2)C=2)=NC=NC1=CC=2OCCN1CCN(CC#C)CC1 SDYDJNLCQKFKIL-UHFFFAOYSA-N 0.000 claims 1
- ZBQDUFLGPNBYCE-UHFFFAOYSA-N 6-chloro-n-[5-(oxan-4-yloxy)-7-[3-(4-prop-2-ynylpiperazin-1-yl)propoxy]quinazolin-4-yl]-[1,3]dioxolo[4,5-b]pyridin-7-amine Chemical compound ClC1=CN=C2OCOC2=C1NC(C1=C(OC2CCOCC2)C=2)=NC=NC1=CC=2OCCCN1CCN(CC#C)CC1 ZBQDUFLGPNBYCE-UHFFFAOYSA-N 0.000 claims 1
- FJNMDDYFEUEVLJ-UHFFFAOYSA-N 6-chloro-n-[5-propan-2-yloxy-7-(2-pyrrolidin-1-ylethoxy)quinazolin-4-yl]-[1,3]dioxolo[4,5-b]pyridin-7-amine Chemical compound C=1C2=NC=NC(NC=3C(=CN=C4OCOC4=3)Cl)=C2C(OC(C)C)=CC=1OCCN1CCCC1 FJNMDDYFEUEVLJ-UHFFFAOYSA-N 0.000 claims 1
- AMXMRGRLUQUEDG-UHFFFAOYSA-N 6-chloro-n-[5-propan-2-yloxy-7-[2-(4-prop-2-ynylpiperazin-1-yl)ethoxy]quinazolin-4-yl]-[1,3]dioxolo[4,5-b]pyridin-7-amine Chemical compound C=1C2=NC=NC(NC=3C(=CN=C4OCOC4=3)Cl)=C2C(OC(C)C)=CC=1OCCN1CCN(CC#C)CC1 AMXMRGRLUQUEDG-UHFFFAOYSA-N 0.000 claims 1
- LHNUBGOLVVVBFV-UHFFFAOYSA-N 6-chloro-n-[7-(2-morpholin-4-ylethoxy)-5-(oxan-4-yloxy)quinazolin-4-yl]-[1,3]dioxolo[4,5-b]pyridin-7-amine Chemical compound ClC1=CN=C2OCOC2=C1NC(C1=C(OC2CCOCC2)C=2)=NC=NC1=CC=2OCCN1CCOCC1 LHNUBGOLVVVBFV-UHFFFAOYSA-N 0.000 claims 1
- CIYSACKPZCOGHC-UHFFFAOYSA-N 6-chloro-n-[7-(2-morpholin-4-ylethoxy)-5-propan-2-yloxyquinazolin-4-yl]-[1,3]dioxolo[4,5-b]pyridin-7-amine Chemical compound C=1C2=NC=NC(NC=3C(=CN=C4OCOC4=3)Cl)=C2C(OC(C)C)=CC=1OCCN1CCOCC1 CIYSACKPZCOGHC-UHFFFAOYSA-N 0.000 claims 1
- LXWLEHANZSZKOO-UHFFFAOYSA-N 6-chloro-n-[7-(2-piperazin-1-ylethoxy)-5-propan-2-yloxyquinazolin-4-yl]-[1,3]dioxolo[4,5-b]pyridin-7-amine Chemical compound C=1C2=NC=NC(NC=3C(=CN=C4OCOC4=3)Cl)=C2C(OC(C)C)=CC=1OCCN1CCNCC1 LXWLEHANZSZKOO-UHFFFAOYSA-N 0.000 claims 1
- CMSYDWDIPDBPGZ-UHFFFAOYSA-N 6-chloro-n-[7-(2-piperidin-1-ylethoxy)-5-propan-2-yloxyquinazolin-4-yl]-[1,3]dioxolo[4,5-b]pyridin-7-amine Chemical compound C=1C2=NC=NC(NC=3C(=CN=C4OCOC4=3)Cl)=C2C(OC(C)C)=CC=1OCCN1CCCCC1 CMSYDWDIPDBPGZ-UHFFFAOYSA-N 0.000 claims 1
- STMAOZDCKQKDGH-UHFFFAOYSA-N 6-chloro-n-[7-(3-morpholin-4-ylpropoxy)-5-(oxan-4-yloxy)quinazolin-4-yl]-[1,3]dioxolo[4,5-b]pyridin-7-amine Chemical compound ClC1=CN=C2OCOC2=C1NC(C1=C(OC2CCOCC2)C=2)=NC=NC1=CC=2OCCCN1CCOCC1 STMAOZDCKQKDGH-UHFFFAOYSA-N 0.000 claims 1
- QOCFWLMWEMNAJO-UHFFFAOYSA-N 6-chloro-n-[7-(3-morpholin-4-ylpropoxy)-5-propan-2-yloxyquinazolin-4-yl]-[1,3]dioxolo[4,5-b]pyridin-7-amine Chemical compound C=1C2=NC=NC(NC=3C(=CN=C4OCOC4=3)Cl)=C2C(OC(C)C)=CC=1OCCCN1CCOCC1 QOCFWLMWEMNAJO-UHFFFAOYSA-N 0.000 claims 1
- NPLQFGONSPDLQX-UHFFFAOYSA-N 6-chloro-n-[7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-propan-2-yloxyquinazolin-4-yl]-[1,3]dioxolo[4,5-b]pyridin-7-amine Chemical compound C=1C2=NC=NC(NC=3C(=CN=C4OCOC4=3)Cl)=C2C(OC(C)C)=CC=1OCCN1CCN(C)CC1 NPLQFGONSPDLQX-UHFFFAOYSA-N 0.000 claims 1
- FFTSIQIZMITTIB-UHFFFAOYSA-N COC(C(OC(C)C)(OCCC)OCC)N(CC)C(C(=O)N(NC)OCCCC)(N(C)C)NCC Chemical compound COC(C(OC(C)C)(OCCC)OCC)N(CC)C(C(=O)N(NC)OCCCC)(N(C)C)NCC FFTSIQIZMITTIB-UHFFFAOYSA-N 0.000 claims 1
- 239000004593 Epoxy Substances 0.000 claims 1
- 230000010933 acylation Effects 0.000 claims 1
- 238000005917 acylation reaction Methods 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000001740 anti-invasion Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- DANWDGOLHZFHLA-UHFFFAOYSA-N n-[7-[2-(3a,4,6,6a-tetrahydro-[1,3]dioxolo[4,5-c]pyrrol-5-yl)ethoxy]-5-(oxan-4-yloxy)quinazolin-4-yl]-6-chloro-[1,3]dioxolo[4,5-b]pyridin-7-amine Chemical compound ClC1=CN=C2OCOC2=C1NC(C=12)=NC=NC2=CC(OCCN2CC3OCOC3C2)=CC=1OC1CCOCC1 DANWDGOLHZFHLA-UHFFFAOYSA-N 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000000464 thioxo group Chemical group S=* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02292736 | 2002-11-04 | ||
| EP03290900 | 2003-04-10 | ||
| PCT/GB2003/004703 WO2004041829A1 (en) | 2002-11-04 | 2003-10-29 | Quinazoline derivatives as src tyrosine kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010167576A Division JP2010270143A (ja) | 2002-11-04 | 2010-07-26 | Ｓｒｃチロシンキナーゼ阻害剤としてのキナゾリン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006506463A JP2006506463A (ja) | 2006-02-23 |
| JP2006506463A5 true JP2006506463A5 (https=) | 2006-11-02 |
| JP4593464B2 JP4593464B2 (ja) | 2010-12-08 |
Family
ID=32313852
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005502127A Expired - Fee Related JP4593464B2 (ja) | 2002-11-04 | 2003-10-29 | Ｓｒｃチロシンキナーゼ阻害剤としてのキナゾリン誘導体 |
| JP2010167576A Pending JP2010270143A (ja) | 2002-11-04 | 2010-07-26 | Ｓｒｃチロシンキナーゼ阻害剤としてのキナゾリン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010167576A Pending JP2010270143A (ja) | 2002-11-04 | 2010-07-26 | Ｓｒｃチロシンキナーゼ阻害剤としてのキナゾリン誘導体 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7462623B2 (https=) |
| EP (1) | EP1562955B1 (https=) |
| JP (2) | JP4593464B2 (https=) |
| KR (1) | KR101089462B1 (https=) |
| AR (1) | AR041884A1 (https=) |
| AT (1) | ATE387451T1 (https=) |
| AU (1) | AU2003278383B2 (https=) |
| BR (1) | BR0315756A (https=) |
| CA (1) | CA2503371C (https=) |
| CO (1) | CO5560578A2 (https=) |
| CY (1) | CY1108061T1 (https=) |
| DE (1) | DE60319410T2 (https=) |
| DK (1) | DK1562955T3 (https=) |
| EG (1) | EG24957A (https=) |
| ES (1) | ES2300619T3 (https=) |
| IL (1) | IL168013A (https=) |
| IS (1) | IS2568B (https=) |
| MX (1) | MXPA05004858A (https=) |
| MY (1) | MY137835A (https=) |
| NO (1) | NO331951B1 (https=) |
| NZ (1) | NZ539408A (https=) |
| PL (1) | PL215161B1 (https=) |
| PT (1) | PT1562955E (https=) |
| RU (1) | RU2350618C2 (https=) |
| SI (1) | SI1562955T1 (https=) |
| TW (1) | TWI320786B (https=) |
| WO (1) | WO2004041829A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7576074B2 (en) | 2002-07-15 | 2009-08-18 | Rice Kenneth D | Receptor-type kinase modulators and methods of use |
| EP2210607B1 (en) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| GB0406445D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
| GB0427697D0 (en) | 2004-12-17 | 2005-01-19 | Astrazeneca Ab | Chemical process |
| KR101313702B1 (ko) * | 2005-02-03 | 2013-10-04 | 와이어쓰 | 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물 |
| WO2009068906A2 (en) * | 2007-11-26 | 2009-06-04 | Astrazeneca Ab | Combinations comprising zd4054 and a src family kinase inhibitor 172 |
| NZ779754A (en) | 2009-01-16 | 2023-04-28 | Exelixis Inc | Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| MX352926B (es) | 2010-09-27 | 2017-12-14 | Exelixis Inc | Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos. |
| AR092289A1 (es) * | 2011-11-14 | 2015-04-15 | Sunshine Lake Pharma Co Ltd | Derivados de aminoquinazolina y sus sales y metodos de uso |
| JP6740354B2 (ja) | 2015-10-05 | 2020-08-12 | ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク | オートファジーの流れ及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法 |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| ES3017461T3 (en) | 2018-09-10 | 2025-05-13 | Mirati Therapeutics Inc | Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer |
| CN119504612B (zh) * | 2024-11-18 | 2026-04-07 | 中国海洋大学 | 一种喹唑啉茋类衍生物及其制备方法和应用 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| SG64322A1 (en) | 1991-05-10 | 1999-04-27 | Rhone Poulenc Rorer Int | Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| PT100905A (pt) | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
| GB9300059D0 (en) * | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| GB9205320D0 (en) * | 1992-03-11 | 1992-04-22 | Ici Plc | Anti-tumour compounds |
| GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US6046206A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
| GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| DE69720965T2 (de) | 1996-02-13 | 2004-02-05 | Astrazeneca Ab | Chinazolinderivate und deren verwendung als vegf hemmer |
| GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| AU2103097A (en) * | 1996-03-15 | 1997-10-10 | Zeneca Limited | Cinnoline derivatives and use as medicine |
| GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| WO1998013350A1 (en) | 1996-09-25 | 1998-04-02 | Zeneca Limited | Qinoline derivatives inhibiting the effect of growth factors such as vegf |
| GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| ES2289791T3 (es) | 1997-08-22 | 2008-02-01 | Astrazeneca Ab | Derivados de oxindolilquinazolina como inhibidores de la angiogenesis. |
| ATE255575T1 (de) | 1998-09-29 | 2003-12-15 | Wyeth Corp | Substituierte 3-cyanochinoline als protein tyrosine kinase inhibitoren |
| US7262201B1 (en) * | 1998-10-08 | 2007-08-28 | Astrazeneca Ab | Quinazoline derivatives |
| PT1154774E (pt) * | 1999-02-10 | 2005-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de angiogenese |
| CA2384282A1 (en) | 1999-09-21 | 2001-03-29 | Astrazeneca Ab | Quinazoline compounds and pharmaceutical compositions containing them |
| GB9922171D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
| KR100881105B1 (ko) | 1999-11-05 | 2009-02-02 | 아스트라제네카 아베 | Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체 |
| AU2001235804A1 (en) | 2000-03-06 | 2001-09-17 | Astrazeneca Ab | Therapy |
| GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| ES2267748T3 (es) | 2000-04-07 | 2007-03-16 | Astrazeneca Ab | Compuestos de quinazolina. |
| UA73993C2 (uk) * | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| WO2002012228A1 (en) | 2000-08-09 | 2002-02-14 | Astrazeneca Ab | Cinnoline compounds |
| WO2002012227A2 (en) | 2000-08-09 | 2002-02-14 | Astrazeneca Ab | Indole, azaindole and indazole derivatives having vegf inhibiting activity |
| WO2002012226A1 (en) | 2000-08-09 | 2002-02-14 | Astrazeneca Ab | Quinoline derivatives having vegf inhibiting activity |
| WO2002016352A1 (en) | 2000-08-21 | 2002-02-28 | Astrazeneca Ab | Quinazoline derivatives |
| AU2001292137A1 (en) | 2000-10-13 | 2002-04-22 | Astrazeneca Ab | Quinazoline derivatives |
| JP2004511479A (ja) | 2000-10-13 | 2004-04-15 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
| AU2002212436A1 (en) | 2000-10-25 | 2002-05-06 | Astrazeneca Ab | Quinazoline derivatives |
| JP4307843B2 (ja) | 2001-04-19 | 2009-08-05 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
| WO2002092579A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
| WO2002092577A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Quinazoline derivatives |
| WO2002092578A1 (en) | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Quinazoline derivatives |
| WO2003008409A1 (en) | 2001-07-16 | 2003-01-30 | Astrazeneca Ab | Quinoline derivatives and their use as tyrosine kinase inhibitors |
| GB0126879D0 (en) | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| AU2002365664A1 (en) | 2001-12-05 | 2003-06-17 | Astrazeneca Ab | Quinoline derivatives as antitumour agents |
| SI1474420T1 (sl) | 2002-02-01 | 2012-06-29 | Astrazeneca Ab | Spojine kinazolina |
| GB0215823D0 (en) | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
| EP1528925B1 (en) | 2002-07-09 | 2009-04-22 | Astrazeneca AB | Quinazoline derivatives for use in the treatment of cancer |
| AU2003249000B2 (en) | 2002-08-09 | 2007-04-05 | Astrazeneca Ab | Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
| GB0218526D0 (en) | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
| GB0223380D0 (en) | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| GB0226434D0 (en) * | 2002-11-13 | 2002-12-18 | Astrazeneca Ab | Combination product |
| KR20050100683A (ko) | 2003-02-13 | 2005-10-19 | 아스트라제네카 아베 | 5-ｆｕ 또는/및 ｃｐｔ-11과 ｚｄ6474의 병용 요법 |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
-
2003
- 2003-10-29 AU AU2003278383A patent/AU2003278383B2/en not_active Ceased
- 2003-10-29 SI SI200331192T patent/SI1562955T1/sl unknown
- 2003-10-29 US US10/533,931 patent/US7462623B2/en not_active Expired - Fee Related
- 2003-10-29 WO PCT/GB2003/004703 patent/WO2004041829A1/en not_active Ceased
- 2003-10-29 MX MXPA05004858A patent/MXPA05004858A/es active IP Right Grant
- 2003-10-29 KR KR1020057007855A patent/KR101089462B1/ko not_active Expired - Fee Related
- 2003-10-29 DK DK03769689T patent/DK1562955T3/da active
- 2003-10-29 JP JP2005502127A patent/JP4593464B2/ja not_active Expired - Fee Related
- 2003-10-29 EP EP03769689A patent/EP1562955B1/en not_active Expired - Lifetime
- 2003-10-29 ES ES03769689T patent/ES2300619T3/es not_active Expired - Lifetime
- 2003-10-29 DE DE60319410T patent/DE60319410T2/de not_active Expired - Lifetime
- 2003-10-29 BR BR0315756-3A patent/BR0315756A/pt not_active IP Right Cessation
- 2003-10-29 CA CA2503371A patent/CA2503371C/en not_active Expired - Fee Related
- 2003-10-29 NZ NZ539408A patent/NZ539408A/en not_active IP Right Cessation
- 2003-10-29 PL PL376255A patent/PL215161B1/pl unknown
- 2003-10-29 RU RU2005117337/04A patent/RU2350618C2/ru not_active IP Right Cessation
- 2003-10-29 PT PT03769689T patent/PT1562955E/pt unknown
- 2003-10-29 AT AT03769689T patent/ATE387451T1/de active
- 2003-10-30 TW TW092130284A patent/TWI320786B/zh not_active IP Right Cessation
- 2003-11-03 MY MYPI20034197A patent/MY137835A/en unknown
- 2003-11-04 AR ARP030104036A patent/AR041884A1/es not_active Application Discontinuation
-
2005
- 2005-04-13 IL IL168013A patent/IL168013A/en not_active IP Right Cessation
- 2005-04-19 NO NO20051900A patent/NO331951B1/no not_active IP Right Cessation
- 2005-04-30 EG EGNA2005000178 patent/EG24957A/xx active
- 2005-05-03 CO CO05042313A patent/CO5560578A2/es not_active Application Discontinuation
- 2005-05-19 IS IS7849A patent/IS2568B/is unknown
-
2008
- 2008-04-24 CY CY20081100460T patent/CY1108061T1/el unknown
-
2010
- 2010-07-26 JP JP2010167576A patent/JP2010270143A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100821446B1 (ko) | 퀴나졸린 유도체 | |
| US7049438B2 (en) | Quinazoline derivatives for treatment of tumours | |
| US7160891B2 (en) | Quinazoline derivatives for the treatment of T cell mediated diseases | |
| US7173135B2 (en) | Substituted 3-cyanoquinolines as MEK inhibitors | |
| US7501516B2 (en) | Quinoline derivatives and their use as tyrosine kinase inhibitors | |
| JP2003535859A5 (https=) | ||
| AU2001278609A1 (en) | Quinazoline derivatives | |
| JP2006506463A5 (https=) | ||
| JP2004511480A (ja) | キナゾリン誘導体 | |
| CA2503371A1 (en) | Quinazoline derivatives as src tyrosine kinase inhibitors | |
| JP2006508944A5 (https=) | ||
| US7157467B2 (en) | Therapeutic use | |
| WO2003047582A1 (en) | Quinoline derivatives as antitumour agents | |
| WO2004108704A1 (en) | Pyrimidin-4-yl 3-cyanoquinoline derivatives for use in the treatment of tumours | |
| US7223756B2 (en) | Quinazoline compounds with therapeutic use | |
| HK1079195B (en) | Quinazoline derivatives as src tyrosine kinase inhibitors |